Clinical trials: Nerve Condition
Melanoma
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or…
- Trial name
- MONETTE (NCT05061134)
- Testing
- Ceralasertib, Durvalumab
- Where
- 66 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- AstraZeneca
Hyperalgesia, Neurodynia
GW406381 In Patients With Peripheral Nerve Injury
The findings from preclinical animal models confirm the peripheral anti-inflammatory/analgesic activity of GW406381 and also suggest contribution of a central site of action to the anti-hyperalgesic efficacy that may not be…
- Conditions
- Hyperalgesia, Neurodynia, Pain, Trauma
- Trial name
- NCT00279032
- Testing
- GW406381
- Where
- 5 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Congestive Heart Failure
Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study
The ANTHEM-HF Study is designed to demonstrate the safety and efficacy of vagus nerve stimulation (VNS) with the Cyberonics VNS Therapy System for the treatment of subjects with symptomatic heart failure.
- Trial name
- ANTHEM-HF (NCT01823887)
- Testing
- Vagus Nerve Stimulation (VNS)
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Cyberonics, Inc.
Advanced Solid Malignancies
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that…
- Trial name
- CERTIS1 (NCT05417594)
- Testing
- AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Merkel Cell Carcinoma
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with treatment-naïve metastatic Merkel Cell Carcinoma
- Trial name
- NCT04874831
- Testing
- domatinostat in combination with avelumab
- Sponsor
- 4SC AG
Recurrent Glioblastoma Multiforme
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody.
- Trial name
- NCT00509301
- Testing
- 131-I-chTNT-1/B MAB
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Peregrine Pharmaceuticals
Pheochromocytoma, Neuroblastoma
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
- Trial name
- NCT00126412
- Testing
- 123I-mIBG (meta-iodobenzylguanidine)
- Where
- United States
- Volunteers
- 251 people
- Sponsor
- GE Healthcare
Malignant Melanoma
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
Patients with metastatic malignant melanoma will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks and sorafenib 400 mg b.i.d.
- Trial name
- NCT00498836
- Testing
- CP-4055, Sorafenib (Nexavar)
- Where
- 6 sites in United States, Norway and 1 more
- Volunteers
- 18 people
- Sponsor
- Clavis Pharma
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Metastatic Melanoma
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
To compare the safety and efficacy of Allovectin-7® versus Dacarbazine (DTIC)or Temozolomide (TMZ) in subjects with recurrent stage 3 or stage 4 melanoma.
- Trial name
- NCT00395070
- Testing
- Allovectin-7®, Dacarbazine (DTIC), Temozolomide (TMZ)
- Where
- 88 sites in United States, Belgium and 12 more
- Volunteers
- 390 people
- Sponsor
- Vical
Melanoma, Malignant Melanoma
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
This study will evaluate the efficacy and safety of T3011 in combination with Cobimetinib in patients with advanced melanoma.
- Trial name
- NCT05756556
- Testing
- T3011 + Cobimetinib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- ImmVira Pharma Co. Ltd
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00084656
- Testing
- ipilimumab, Tyrosinase/gp100/MART-1 Peptides
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
- Trial name
- NCT05879822
- Testing
- INCB099280
- Where
- 54 sites in Brazil, China and 7 more
- Volunteers
- 73 people
- Sponsor
- Incyte Corporation
Melanoma
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the…
- Trial name
- LOGIC-2 (NCT02159066)
- Testing
- LGX818, MEK162, LEE011
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 158 people
- Sponsor
- Pfizer
Melanoma
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of melanomas.
- Trial name
- NCT03932253
- Testing
- FCN-159
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Osteoarthritic Knee Pain
Freedom-1 Study for Chronic Knee Pain
To demonstrate the potential benefits and risk of active sub-threshold stimulation in the treatment of chronic knee pain as compared to subjects that did not have active stimulation.
- Trial name
- NCT03877653
- Testing
- Wireless neuromodulation
- Where
- 13 sites in United States
- Volunteers
- 100 people
- Sponsor
- Curonix LLC
Neuromyelitis Optica Spectrum Disorders
A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.
- Trial name
- NCT06212245
- Testing
- Inebilizumab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Hansoh BioMedical R&D Company
Leber's Hereditary Optic Neuropathy
Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
Expanded access Protocol to treat LHON subjects with EPI743
- Trial name
- NCT02300753
- Testing
- EPI-743
- Where
- United States
- Sponsor
- Edison Pharmaceuticals Inc
Leber's Hereditary Optic Neuropathy
Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study
Expanded Access Program for Idebenone in Patients with Leber's Hereditary Optic Neuropathy who completed the LEROS Study
- Trial name
- US EAP LHON (NCT04381091)
- Testing
- Idebenone 150 MG Oral Tablet
- Sponsor
- Santhera Pharmaceuticals
Metastatic Melanoma
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
Phase IV, open-label, randomized, two-arm, multi-center study in patients with metastatic melanoma who are treatment naïve or have previously received a single non-immunologic therapy.
- Trial name
- PROCLIVITY02 (NCT01856023)
- Testing
- High Dose Interleukin-2, Ipilimumab
- Where
- 12 sites in United States
- Volunteers
- 29 people
- Sponsor
- Clinigen, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.